Kairos Pharma Announces Initial Public Offering
Kairos Pharma, Ltd. has officially priced its initial public offering (IPO), a crucial move for the clinical-stage biopharmaceutical company that's known for developing groundbreaking cancer treatments. The shares will be sold at $4.00 each, with a total of 1,550,000 shares of common stock available. This reflects a strong interest in their innovative efforts to tackle cancer drug resistance and improve immune response.
Offering Details
Along with the main offering, Kairos Pharma has also granted underwriters a 45-day option to acquire an additional 232,500 shares at the same public offering price. This strategic option is a proactive step to potentially meet increased investor demand. The shares are expected to begin trading on the NYSE American, using the ticker symbol “KAPA.”
Financial Outlook
The gross proceeds from this IPO are projected to be around $6.2 million, not factoring in underwriting fees and other related costs. The closing of this offering is anticipated to happen soon, pending the usual closing conditions. These funds will be vital for advancing their top product, ENV 105, through its Phase 1 trial targeting lung cancer and Phase 2 trial focusing on prostate cancer. This financial influx underscores Kairos Pharma's commitment to addressing pressing health challenges through innovative research in oncology.
Future Investments
In addition to using this funding to support clinical trials, the company is also aiming to advance its pipeline by developing preclinical candidates such as KROS 101. This small molecule agonist is designed to stimulate T cell growth and boost their effectiveness against cancer. The careful allocation of resources showcases Kairos Pharma's dedication to tackling intricate challenges in cancer treatment.
Underwriting Details
Boustead Securities, LLC is leading the underwriting process for this IPO, with assistance from EF Hutton LLC. This partnership illustrates the financial sector's confidence in Kairos Pharma's goals and potential within the biopharmaceutical industry.
Regulatory Compliance
The registration statement for the IPO has been filed with and approved by the Securities and Exchange Commission (SEC). This step ensures compliance and transparency, which are essential for attracting prospective investors. Further details about the offering are available through the SEC’s resources.
About Kairos Pharma
Kairos Pharma, located in Los Angeles, California, is dedicated to building a diverse pipeline of oncology therapeutics. The company leverages advancements in structural biology to confront the critical challenges of drug resistance and immune suppression in cancer patients. With a robust lineup of innovative drug candidates, Kairos Pharma stands out as a forward-looking leader in the biopharmaceutical field.
Frequently Asked Questions
What amount is Kairos Pharma expecting to raise from their IPO?
Kairos Pharma aims to raise about $6.2 million from the IPO before accounting for underwriting fees.
When will trading for Kairos Pharma shares begin?
Trading for Kairos Pharma shares is anticipated to start shortly after the closing date of the offering under the ticker symbol “KAPA.”
What will the proceeds from the IPO be allocated towards?
The proceeds will mainly be used to fund clinical trials for the lead product candidate ENV 105 and advance preclinical candidates like KROS 101.
Who are the underwriters involved in this offering?
The lead managing underwriter for this offering is Boustead Securities, LLC, with EF Hutton LLC serving as the co-managing underwriter.
Where can investors find more information about the IPO?
Investors can refer to the SEC's website and Kairos Pharma's investor contacts for additional information regarding the IPO.
